OTC Markets OTCPK - Delayed Quote ? USD Clarity Pharmaceuticals Ltd (CLRPF) Follow Compare 4.5520 0.0000 (0.00%) At close: October 18 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Copper-67 SAR-bisPSMA updates Copper-67 SAR-bisPSMA updates PR Newswire ? 4 days ago CLRPF 0.00% Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it will be commencing a pivotal Phase III trial of its 64Cu-SAR-bisPSMA diagnostic in patients with BCR of prostate cancer following a successful end of phase meeting with the U.S. FDA. The trial, named AMPLIFY (64Cu-SAR-bisPSMA Positron Emission To PR Newswire ? 6 days ago CLRPF 0.00% Market Sentiment Around Loss-Making Clarity Pharmaceuticals Ltd (ASX:CU6) Clarity Pharmaceuticals Ltd ( ASX:CU6 ) is possibly approaching a major achievement in its business, so we would like... Simply Wall St. ? last month CLRPF 0.00% SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an update on the safety review of the first 3 participants enrolled in cohort 4 of the SECuRE trial who received 2 doses of 67Cu-SAR-bisPSMA. Cohort 4 is the final cohort in the dose escalation phase of the study, with participants receiving a minimum of 2 and a m PR Newswire ? last month CLRPF 0.00% Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Clarity... Simply Wall St. ? last month CLRPF 0.00% Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions with suspected metastasis who are PR Newswire ? last month CLRPF 0.00% Codan Leads Three Undervalued Small Caps With Insider Actions In Australia In recent trading sessions, the Australian market has shown mixed signals with the ASX200 marginally up by 0.1%. Notably, the IT sector outperformed, gaining 0.9%, while materials faced a downturn, nearly losing 1%. In such a fluctuating environment, identifying undervalued small-cap stocks like Codan that show potential for growth becomes crucial for investors looking for opportunities amidst broader market movements. Simply Wall St. ? 3 months ago NURPF 0.00% CODAF CLRPF 0.00% Exploring Undervalued Small Caps With Insider Actions In June 2024 As global markets exhibit a mix of cautious optimism and selective growth, with the S&P 500 reaching new highs and modest gains across major indices, investors are keenly observing market dynamics. In this environment, undervalued small-cap stocks, particularly those with insider buying actions, could present intriguing opportunities for discerning investors looking to potentially capitalize on overlooked value in the current economic landscape. Simply Wall St. ? 3 months ago HMDPF CLRPF 0.00% 1277.HK Exploring Undervalued Small Caps With Insider Actions In Australia June 2024 In recent times, the Australian market has shown a steady increase, rising 8.9% over the past year despite remaining flat in the last week. Given these conditions and with earnings expected to grow by 14% annually in the near future, undervalued small caps with insider buying actions can present intriguing opportunities for investors looking to potentially benefit from market inefficiencies. Simply Wall St. ? 3 months ago CLRPF 0.00% NURPF 0.00% CODAF Is Clarity Pharmaceuticals Ltd (ASX:CU6) Trading At A 48% Discount? Key Insights Clarity Pharmaceuticals' estimated fair value is AU$9.82 based on 2 Stage Free Cash Flow to Equity Clarity... Simply Wall St. ? 4 months ago CLRPF 0.00% Clarity's theranostic prostate cancer trial advances to multi-dose phase Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the successful completion of cohort 3 and advancement to cohort 4, the first multi-dose cohort in the SECuRE trial. PR Newswire ? 7 months ago CLRPF 0.00% Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127)[1]. PR Newswire ? 7 months ago CLRPF 0.00% First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE. PR Newswire ? 9 months ago CLRPF 0.00% Registrational Phase III CLARIFY trial in prostate cancer commences Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)[1], with the initiation of the first clinical site at the Urology Cancer Center / XCancer Omaha, NE. PR Newswire ? 10 months ago CLRPF 0.00% First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient ever to be dosed with two cycles of 8GBq of 67Cu-SAR-bisPSMA has had a drop in PSA to undetectable levels, undetectable disease using PET and a near complete response to treatment under RECIST. The patient received the first c PR Newswire ? 10 months ago CLRPF 0.00% Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the successful completion of the first stage of cohort 3 of the Phase I/IIa theranostic trial, SECuRE, evaluating 64Cu/67Cu-SAR-bisPSMA in patients with mCRPC where 3 participants have been treated at the highest dose level of 12GBq of 67Cu-SAR-bisPSMA. No adverse PR Newswire ? 10 months ago CLRPF 0.00% Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE (NCT05407311)[1], for participants with PSMA-negative prostate cancer. PR Newswire ? 11 months ago CLRPF 0.00% Clarity and PSI kick off SAR-bisPSMA Phase III Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract research organisation committed to on-time enrollment in radiopharmaceutical clinical trials, have entered into an agreement and have commenced work towards Clarity's Phase III diagnostic trial of SAR-bisPSMA in prostate cancer participants, CLA PR Newswire ? 11 months ago CLRPF 0.00% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] Return CLRPF S&P/ASX 200 [XJO] YTD -1.26% +5.99% 1-Year -1.26% +5.99% 3-Year -1.26% +5.99%
